Novartis | NVS - Operating Profit

Stock Price
148.08
Daily Change
-1.76 -1.17%
Monthly
-1.15%
Yearly
35.13%
Q2 Forecast
145.13

Novartis reported $4.06B in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Amgen USD 3.83B 130M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Bausch Health Companies USD 489M 230M Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Canopy Growth CAD -12.66M 1.64M Dec/2025
Corcept Therapeutics USD -49.6M 54.09M Mar/2026
Drreddys Laboratories INR 14.33B 2.51B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Glaxosmithkline GBP 2.3B 1.46B Dec/2025
J&J USD 6.62B 1.03B Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Novartis USD 4.24B 171M Mar/2026
Novartis USD 4.06B 521M Dec/2025
Pacira USD 4.62M 1.43M Mar/2026
Perrigo USD 33.6M 50.8M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 75.49M 7M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
Sanofi EUR 1.5B 2.29B Dec/2025
Supernus Pharmaceuticals USD -35.25M 49.07M Mar/2026
Zoetis USD 865M 30M Mar/2026